Rates of CNS progression in patients with advanced NSCLC harboring somatic EGFR mutations and treated with gefitinib or erlotinib.

• DOI: 10.1200/jco.2010.28.15_suppl.7543
• Publication Date: 2017-02-24T02:41:10Z
• Authors: S. Heon; B. Y. Yeap; G. J. Britt; M. S. Rabin; D. M. Jackman; B. E. Johnson
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

7543 Background: Gefitinib and erlotinib can penetrate into the CNS elicit intracranial responses. However, there is incomplete data about their impact on development control of metastases. The experience at DFCI was reviewed to determine risk progression in patients with somatic EGFR mutations advanced NSCLC treated initially gefitinib or erlotinib. Methods: We identified stage IIIB IV as initial therapy for between 1/01 2/09. cumulative brain relapse calculated using death a competing risk. Results: Of 100 eligible patients, 19 had metastases (BM) time diagnosis NSCLC; 17 them received before initiating To date, 83 have progressed after median potential follow-up 41.3 months. progression-free survival entire cohort 13.2 28 developed progression, 8 whom history previously BM. Carcinomatous meningitis occurred patients; 4 synchronous site 10 sole failure 5 these. 1- 2-year actuarial rates were 7% 19%, respectively. lower those 81 without involvement compared pre-existing disease (6% vs 11% 1 yr, 13% 49% 2 yrs). overall from TKI initiation 33.6 months (95% CI, 25.3-40.3 months). No difference noted (30.3 39.1 months, p = 0.49). Conclusions: Patients appear published 20% 40% unselected historical controls receiving chemotherapy. Distinguishing biological differences therapeutic effect patterns will be important further guide first-line post IPASS trial era. Author Disclosure Employment Leadership Position Consultant Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, KEW Group Diagnostics, Millennium, Pfizer Celgene Roche Genzyme